IgA Nephropathy

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy (RAINIER)

This study tests if a new medicine named povetacicept can help people with immunoglobulin A

nephropathy (IgAN).

In this study, people with IgAN will be given povetacicept or placebo.

The main goals of the study are to:

To evaluate the efficacy of povetacicept compared with placebo in reducing proteinuria
To evaluate the efficacy of povetacicept compared with placebo in preserving renal function

Paused to recruitment in EU

Professor Peter Conlon

Vertex

Network Partners